On February 7, 2022 Nordic Pharma reported that they have entered into an agreement with SANOFI to fully acquire the rights to ALTIM (cortivazol), a legacy product in France (Press release, Nordic Pharma, FEB 7, 2022, View Source [SID1234607876]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ALTIM contains a 3.75mg/1.5ml cortivazol suspension for injection, presented in a pre-filled syringe, and is approved in France in Rheumatology indications, where a local corticosteroid treatment is required.
See prescribing information: Résumé des caractéristiques du produit – ALTIM 3,75 mg/1,5 ml, suspension injectable en seringue pré-remplie – Base de données publique des médicaments (medicaments.gouv.fr)
This acquisition supports Nordic Pharma’s strategy to grow its proprietary portfolio and to become a key player in Rheumatology in France and beyond.
ALTIM was commercialized in France since the 70’s and subsequently withdrawn from the French market by Sanofi in 2018 due to manufacturing issues. It is the intention of Nordic Pharma to re-engineer the process and the manufacturing for both the active substance and the finished product to allow the product to be re-launched onto the French market at the earliest possibility as the product is still requested by clinicians.
Jean-Michel Quinot, CEO of Nordic Pharma stated:" We are very pleased to have reached an agreement with Sanofi allowing us to re-introduce ALTIM into the French market. Nordic Pharma is dedicated to providing Patients and Physicians with innovative medications addressing significant unmet medical needs. We are very eager to further expand our successful collaboration with Sanofi."
Veronique Rebours-Mory, CSO of Nordic Pharma stated: "Physicians are still demanding this unique treatment option for Rheumatology patients, and despite the challenge and investment needed, we are committed to solving the manufacturing issues that led to the discontinuation of the product."